Ravi Patel
About Ravi Patel
Ravi Patel is the Senior Director of Corporate Strategy at Bristol Myers Squibb in Princeton, New Jersey, with extensive experience in business development, consulting, and scientific research.
Company
Ravi Patel is currently working at Bristol Myers Squibb, where he holds the position of Senior Director, Corporate Strategy. Bristol Myers Squibb is a renowned biopharmaceutical company based in Princeton, New Jersey, United States.
Title
Ravi Patel serves as the Senior Director of Corporate Strategy at Bristol Myers Squibb. His work involves leading various strategic initiatives, including integration optimization efforts for multiple M&A transactions and developing growth strategies for different therapeutic areas.
Education and Expertise
Ravi Patel holds a Master of Business Administration (MBA) with a focus on Finance, Strategy, and Management from Cornell Johnson Graduate School of Management. He also earned a Master of Science (MS) from UMDNJ/Rutgers and a Bachelor of Science (BS) in Biomedical Engineering from Rutgers University. His extensive educational background underpins his expertise in corporate strategy, finance, and biomedical engineering.
Professional Background
Before his current role, Ravi Patel served as the Senior Director of Business Development Analytics at Bristol Myers Squibb from 2020 to 2022. Prior to that, he held various positions at Syneos Health Consulting, including Senior Engagement Manager and Engagement Manager in the Greater New York City Area. He also worked at inVentiv Health Consulting (formerly Campbell Alliance) in roles such as Senior Consultant and Consultant in the Corporate Development Practice. His early career included positions at Big Red Venture Fund, Johnson & Johnson, and the University of Pennsylvania School of Medicine.
Achievements
Ravi Patel has played a significant role in developing therapeutic area growth strategies, particularly for rare diseases and urology. He has conducted market opportunity assessments for new oncology treatments and has extensive experience in forecasting and valuation for clinical development strategies in neurology. Additionally, he has worked on indication and disease assessments for pain management therapies and has a strong background in diagnostics, pharmaceuticals, biotechnology, and medical devices.